GlassScriptPhysician profile
Madan Kumar Nanjunde Gowda
NPI 1548413230
$3,952.57
in general payments reported to CMS, 2019-2025
23 companies · $1,164 in 2025
The $1,164 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $156 · 2021: $496 · 2022: $531 · 2023: $530 · 2024: $1,076 · 2025: $1,164.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,770.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,769.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $580.41 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $430.59 | 2021-2024 | |
| Vifor Pharma, INC. | $344.12 | 2020-2025 | Veltassa |
| Calliditas Therapeutics US INC. | $310.06 | 2023-2025 | Tarpeyo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $309.78 | 2023-2025 | Jardiance |
| Amgen INC. | $288.48 | 2021-2025 | Tavneos, Parsabiv, Krystexxa |
| Akebia Therapeutics INC | $258.09 | 2020-2025 | Auryxia, Vafseo |
| Otsuka America Pharmaceutical, INC. | $233.23 | 2022-2025 | Jynarque |
| Travere Therapeutics, INC. | $204.03 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $157.52 | 2021-2024 | Farxiga |
| Ardelyx, INC. | $151.30 | 2023-2025 | Ibsrela |
| Opko Pharmaceuticals, LLC | $149.37 | 2020-2021 | |
| Glaxosmithkline, LLC. | $126.16 | 2022-2023 | Jesduvroq |
| Mallinckrodt Hospital Products INC. | $102.58 | 2020-2025 | Terlivaz |
| Aurinia Pharma U.S., INC. | $69.99 | 2021-2025 | Lupkynis |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $67.87 | 2025 | Ozempic, Rybelsus |
| Alexion Pharmaceuticals, INC. | $64.08 | 2021-2023 | Soliris |
| Ani Pharmaceuticals, INC. | $31.53 | 2024 | Purified Cortrophin Gel |
| Fresenius USA Marketing, INC. | $17.86 | 2023 | Velphoro |
| Daiichi Sankyo INC. | $16.47 | 2022 | |
| Kyowa Kirin, INC. | $15.08 | 2023 | Crysvita |
| Takeda Pharmaceuticals U.S.A., INC. | $12.69 | 2020 | |
| Medtronic, INC. | $11.28 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Madan Kumar Nanjunde Gowda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.